Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
story of the week
Published in Oncology

Journal Scan / Research · November 14, 2019

Efficacy of Pembrolizumab in Non-Colorectal High Microsatellite Instability/Mismatch Repair–Deficient Cancer

Journal of Clinical Oncology

 

Additional Info

Disclosure statements are available on the authors' profiles:

Journal of Clinical Oncology
Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study
J. Clin. Oncol 2019 Nov 04;[EPub Ahead of Print], A Marabelle, DT Le, PA Ascierto, AM Di Giacomo, A De Jesus-Acosta, JP Delord, R Geva, M Gottfried, N Penel, AR Hansen, SA Piha-Paul, T Doi, B Gao, HC Chung, J Lopez-Martin, YJ Bang, RS Frommer, M Shah, R Ghori, AK Joe, SK Pruitt, LA Diaz

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading